hims semaglutide results expansion may not come in time for risky GLP-1 business Wegovy® Pill | Hims

Patients taking the drug for four years lost and sustained an average of 10% of their bodyweight while remaining on the medicine, the researchers found, compared to just 1.5% in the placebo group

Don't Settle for High U.S

She also believes that it's important to expand the criteria for obesity so that more people qualify for these drugs through the proper channels, but says it's crucial that patients receive ongoing care from a medical professional who has been licensed by the American Board of Obesity Medicine

Retatrutide is expected to have strong effects as well, but further data is needed before making a final determination